ArticleAmerican heart journal plus : cardiology research and practice2024

Assessment of the U.S. Food and Drug Administration's risk evaluation and mitigation strategy (REMS) for prasugrel (EFFIENT): A narrative review.

Thomas Metkus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.